

Payment Policy | Phrenic Nerve Stimulation for Central Sleep Apnea



EFFECTIVE DATE: 07|01|2022

POLICY LAST UPDATED: 03|16|2022

OVERVIEW

Central sleep apnea (CSA) is characterized by sleep-disordered breathing due to diminished or absent respiratory effort. Central sleep apnea may be idiopathic or secondary (associated with a medical condition, drugs, or high altitude breathing). The use of positive airway pressure devices is currently the most common form of therapy for CSA. An implantable device that stimulates the phrenic nerve in the chest is a potential alternative treatment. The battery-powered device sends signals to the diaphragm in order to stimulate breathing and normalize sleep-related breathing patterns.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

The use of phrenic nerve stimulation for central sleep apnea is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

The use of phrenic nerve stimulation for central sleep apnea is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND

Central Sleep Apnea

Central sleep apnea (CSA) is characterized by repetitive cessation or decrease in both airflow and ventilatory effort during sleep. Central sleep apnea may be idiopathic or secondary (associated with a medical condition such as congestive heart failure, drugs, or high altitude breathing). Apneas associated with Cheyne-Stokes respiration are common among individuals with heart failure (HF) or who have had strokes, and account for about half of the population with CSA. Central sleep apnea is less common than obstructive sleep apnea. Based on analyses of a large community-based cohort of participants 40 years of age and older in the Sleep Heart Health Study, the estimated prevalence of CSA and obstructive sleep apnea are 0.9% and 47.6%, respectively.¹ Risk factors for CSA include age (>65 years), male gender, history of HF, history of stroke, other medical conditions (acromegaly, renal failure, atrial fibrillation, low cervical tetraplegia, and primary mitochondrial diseases), and opioid use. Individuals with CSA have difficulty maintaining sleep and therefore experience excessive daytime sleepiness, poor concentration, and morning headaches, and are at higher risk for accidents and injuries.

Treatment

The goal of treatment is to normalize sleep-related breathing patterns. Because most cases of CSA are secondary to an underlying condition, central nervous system pathology, or medication side effects, treatment of the underlying condition or removal of the medication may improve CSA. Treatment recommendations differ depending on the classification of CSA as either hyperventilation-related (most common, including primary CSA and those relating to HF or high altitude breathing) or hypoventilation-related (less common, relating to central nervous system diseases or use of nervous system suppressing drugs such as opioids).

For individuals with hyperventilation-related CSA, continuous positive airway pressure (CPAP) is considered first-line therapy. Due to CPAP discomfort, individual compliance may become an issue. Supplemental oxygen during sleep may be considered for individuals experiencing hypoxia during sleep or who cannot tolerate CPAP. Individuals with CSA due to HF with an ejection fraction >45%, and who are not responding with CPAP and oxygen therapy, may consider bilevel positive airway pressure or adaptive servo-ventilation (ASV) as second-line therapy. Bilevel positive airway pressure devices have 2 pressure settings, 1 for inhalation and 1 for exhalation. Adaptive servo-ventilation uses both inspiratory and expiratory pressure, and titrates the pressure to maintain adequate air movement. However, a clinical trial reported increased cardiovascular mortality with ASV in individuals with CSA due to HF and with an ejection fraction <45%,² and therefore, ASV is not recommended for this group.

For individuals with hypoventilation-related CSA, first-line therapy is bilevel positive airway pressure.

Pharmacologic therapy with a respiratory stimulant may be recommended to individuals with hyper- or hypoventilation CSA who do not benefit from positive airway pressure devices, though close monitoring is necessary due to the potential for adverse effects such as rapid heart rate, high blood pressure, and panic attacks.

Phrenic Nerve Stimulation

Several phrenic nerve stimulation systems are available for individuals who are ventilator dependent. These systems stimulate the phrenic nerve in the chest, which sends signals to the diaphragm to restore a normal breathing pattern. Currently, there is 1 phrenic nerve stimulation device approved by the U.S. Food and Drug Administration (FDA) for CSA, the remede System (Respicardia, Inc.). A cardiologist implants the battery powered device under the skin in the right or left pectoral region using local anesthesia. The device has 2 leads, 1 to stimulate a phrenic nerve (either the left pericardiophrenic or right brachiocephalic vein) and 1 to sense breathing. The device runs on an algorithm that activates automatically at night when the individual is in a sleeping position, and suspends therapy when the individual sits up. Individual-specific changes in programming can be conducted externally by a programmer.

Regulatory Status

In October 2017, the FDA approved the remede System (Respicardia, Inc; Minnetonka, MN) through the premarket approval application process. The approved indication is for treatment of moderate to severe CSA in adults. Follow-up will continue for 5 years in the post-approval study. FDA product code: PSR.

CODING

The following code(s) are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

- 0424T** Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)
- 0425T** Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only
- 0426T** Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only
- 0427T** Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only

- 0432T** Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only
- 0433T** Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only
- 0434T** Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea
- 0435T** Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session
- 0436T** Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study

For the following code(s), please refer to the Related Policy Removal of Implantable Devices.

- 0428T** Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only
- 0429T** Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only
- 0430T** Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only

The following code is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products for the replacement. The removal is considered medically necessary when the medical criteria found in the Removal of Implantable Devices policy are met:

- 0431T** Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only

RELATED POLICIES

Removal of Implantable Devices

PUBLISHED

Provider Update, May 2022

REFERENCES

1. Donovan LM, Kapur VK. Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. *Sleep*. Jul 01 2016; 39(7): 1353-9. PMID 27166235
2. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N Engl J Med*. Sep 17 2015; 373(12): 1095-105. PMID 26323938
3. Costanzo MR, Augostini R, Goldberg LR, et al. Design of the remede System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. *J Card Fail*. Nov 2015; 21(11): 892-902. PMID 26432647
4. Costanzo MR, Ponikowski P, Javaheri S, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *Lancet*. Sep 03 2016; 388(10048): 974-82. PMID 27598679
5. Costanzo MR, Ponikowski P, Javaheri S, et al. Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. *Am J Cardiol*. Jun 01 2018; 121(11): 1400-1408. PMID 29735217
6. Fox H, Oldenburg O, Javaheri S, et al. Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. *Sleep*. Oct 21 2019; 42(11). PMID 31634407
7. Costanzo MR, Ponikowski P, Coats A, et al. Phrenic nerve stimulation to treat individuals with central sleep apnoea and heart failure. *Eur J Heart Fail*. Dec 2018; 20(12): 1746-1754. PMID 30303611
8. Abraham WT, Jagielski D, Oldenburg O, et al. Phrenic nerve stimulation for the treatment of central sleep apnea. *JACC Heart Fail*. May 2015; 3(5): 360-369. PMID 25770408
9. Jagielski D, Ponikowski P, Augostini R, et al. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remede (R) System. *Eur J Heart Fail*. Nov 2016; 18(11): 1386-1393. PMID 27373452
10. Fox H, Bitter T, Horstkotte D, et al. Long-Term Experience with First-Generation Implantable Neurostimulation Device in Central Sleep Apnea Treatment. *Pacing Clin Electrophysiol*. May 2017; 40(5): 498-503. PMID 28211952

11. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep*. Jan 01 2012; 35(1): 17-40. PMID 22215916
12. Aurora RN, Bista SR, Casey KR, et al. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses. *J Clin Sleep Med*. May 15 2016; 12(5): 757-61. PMID 27092695

DRAFT

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your individuals. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

